<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911127-0090</DOCNO><DOCID>911127-0090.</DOCID><HL>   Financing Business:   Genetic Therapy Inc.</HL><DATE>11/27/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C17</SO><CO>   GTII</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)STOCK AND BOND REGISTRATIONS, PRICINGS (REG)STOCK MARKET, OFFERINGS (STK)</IN><NS>BOND AND STOCK REGISTRATIONS AND PRICINGS (REG)STOCK andamp; OTHER MARKET NEWS (STK)</NS><RE>MARYLAND (MD)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   GENETIC THERAPY Inc., Gaithersburg, Md., said it isplanning a public offering of 1.5 million shares to help fundits research and development. The disclosure, in aregistration statement with the Securities and ExchangeCommission, came only a day after Genetic Therapy's entryinto a broad series of agreements with a unit of Sandoz Ltd.of Switzerland to develop and commercialize certaingene-transfer technology. The Sandoz unit, in a related move,purchased 470,357 Genetic Therapy common shares, or a 6.1%stake, for $10 million. Genetic Therapy said the proposedpublic offering would be underwritten by a syndicate led bySmith Barney, Harris Upham andamp; Co. and Montgomery Securities.Genetic Therapy shares were quoted yesterday at $12.75, down$1.125 in over-the-counter trading, giving the offering anindicated value of about $19 million.</LP><TEXT/></DOC>